Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $17.57 Consensus PT from Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have received a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $17.57.

Several research analysts have issued reports on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Friday, May 10th. Morgan Stanley lowered their price objective on Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Friday, May 10th. Wells Fargo & Company started coverage on Amicus Therapeutics in a research note on Thursday, May 30th. They issued an “overweight” rating and a $18.00 price target for the company. JPMorgan Chase & Co. dropped their price objective on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, March 18th. Finally, UBS Group decreased their target price on Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, May 10th.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $9.81 on Friday. Amicus Therapeutics has a 52 week low of $9.02 and a 52 week high of $14.57. The company has a quick ratio of 2.61, a current ratio of 3.03 and a debt-to-equity ratio of 2.97. The stock has a market cap of $2.91 billion, a P/E ratio of -20.02 and a beta of 0.71. The business’s 50 day moving average price is $9.93 and its 200-day moving average price is $11.64.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.04. The business had revenue of $110.40 million for the quarter, compared to the consensus estimate of $111.19 million. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. The company’s revenue for the quarter was up 27.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.18) earnings per share. Equities research analysts anticipate that Amicus Therapeutics will post -0.12 earnings per share for the current fiscal year.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total value of $75,525.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $8,928,605.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amicus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Comerica Bank increased its holdings in Amicus Therapeutics by 0.8% during the fourth quarter. Comerica Bank now owns 103,418 shares of the biopharmaceutical company’s stock valued at $1,468,000 after buying an additional 774 shares during the last quarter. Van ECK Associates Corp increased its stake in shares of Amicus Therapeutics by 23.1% in the 4th quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 873 shares in the last quarter. Franklin Resources Inc. raised its holdings in Amicus Therapeutics by 2.3% in the 4th quarter. Franklin Resources Inc. now owns 54,943 shares of the biopharmaceutical company’s stock worth $780,000 after purchasing an additional 1,258 shares during the period. American International Group Inc. lifted its position in Amicus Therapeutics by 0.9% during the fourth quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock valued at $2,004,000 after purchasing an additional 1,298 shares in the last quarter. Finally, Alps Advisors Inc. grew its holdings in Amicus Therapeutics by 1.3% during the third quarter. Alps Advisors Inc. now owns 211,895 shares of the biopharmaceutical company’s stock valued at $2,577,000 after purchasing an additional 2,716 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.